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A key limitation to the analysis of the immune response in man has been the difficulty of defining and characterizing the unique surface components of human lymphocyte subpopulations. Whereas specific lymphocyte differentiation antigens have been defined by heterologous antibodies from immune sera, many of the technical limitations of this approach can now be resolved by the generation of monoclonal antibodies with somatic cell hybridization techniques (1) . We have therefore applied these techniques to study differentiation antigens on human T lymphocytes.
In this report we define and characterize by a monoclonal antibody a surface antigen complex of 69,000 and 71,000 daltons, p69,71 (Leu 1), 1 that has a thymusdependent distribution on normal lymphocytes, but shares determinants with leukemic cells from patients with B-type chronic lymphatic leukemia. The distribution and molecular nature of p69,71 suggest that this complex may be related to the GLX system in the mouse (2) .
Materials and Methods

Production of Monoclonal Antibody
IMMUNIZATION AND SOMATIC CELL HYBRIDIZATION. BALB/c mice were immunized subcutaneously with 1 × l0 T sheep erythrocyte (SRBC)-rosetting human peripheral blood lymphocytes and boosted three times at 2-wk intervals. 3 d after the last immunization, the splenocytes were fused with P3 × 63 Ag-8 myeloma cells, and cultured in RPMI-1640 (Grand Island Biological Co., Grand Island, N. Y.) that contained 15% fetal calf serum (FCS) and hypoxanthineaminiopterine-thymidine following the procedure developed by K6hler and Milstein (1) .
SELECTION AND CLONING OF HYBRIDIZED CELLS. Approximately 10-14 d later, supernates were collected from wells with hybrid cell growth and tested for antibody specific to T cells by indirect immunofiuorescent analysis as described below. Hybrids from wells that contained antibodies specific to peripheral T lymphocytes were harvested and cloned by a limitingdilution method in the presence of feeder cells (3) and plated into a Linbro 96-well fiat-bottom tissue culture plate (Linbro Chemical Co., Hamden, Conn.) for subsequent screening and recloning.
NUDE MICE SERUM THAT CONTAINED MONOCLONAL ANTIBODY. After recloning positive hybrids 8-10 times, 1 x l07 hybrid cells were implanted subcutaneously into n u / n u mice on a Swiss strain background. Sera were obtained from these tumor-bearing mice ~3 wk later. 
Specificity Analysis of the Monoclonal Antibody
ISOLATION OF T LYMPHOCYTE POPULATION. Mononuclear cells were separated from fresh heparinized blood of normal individuals by Ficoll (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N.J.) -Hypaque (Winthrop Laboratories, New York) density gradient centrifugation. T cells were isolated from other mononuclear cells by a two-step process that involved passage over nylon-wool columns followed by E-rosette formation and density gradient centrifugation (4) .
ISOLATION OF MONOCYTES. Monocytes were isolated by plating peripheral blood mononuclear cells at a density of 5 × 106/ml in RPMI-1640 that contained 10% FCS over glass Petri dishes for 2 h. The nonadherent cells were removed by vigorous lavage, and the adherent cells are recovered after incubation for 1 h at 37°C in medium that contained 0.1% EDTA. Greater than 90% of these cells had the morphological characteristics of monocytes or macrophages.
ISOLATION OF a CELLS. Lymphocytes depleted of phagocytic cells by iron carbonyl treatment were brought to a concentration of 10-20 × 106/ml and mixed at a 1 : 1 vol with a 5% suspension of neuraminidase-treated SRBC (4). The non-E-rosette-forming cells (B cells) were separated from the E-rosette-forming cells on Ficoll-Hypaque gradients.
CYTOFLUOROGRAPHIC ANALYSIS. Cytofluorographic analysis of all cell populations was performed by indirect immunofluorescence with fuorescent-conjugated F(ab')2 fragments of affinity-purified goat anti-mouse IgG (G/M FITC) on a cytofluorograph (model FC200-4800 A50, Ortho Instruments, Westwood, Mass.) as previously described (5).
In brief, 5 × 105 cells were treated with 0.15 ml of serum from mice bearing the a-Leu 1-secreting tumors at a 1:104 dilution, incubated at 4°C for 1 h, and washed twice. The cells were then mixed with 0.15 ml of G/M FITC at a 1:20 dilution for 1 h, washed three times, and then analyzed on the cytofluorograph. Background staining was obtained by using a serum from a nude mouse that was tumor free.
Biochemical Analysis of the Target Antigen
IODINATION OF THE CELL SURFACE. A modification of the method of Marchalonis et al. (6) was used to iodinate the surface as described previously (7).
IMMUNOPRECIPITATION. For immunoprecipitation experiments, 100 #1 of the tumor-bearing nude mouse serum at a 1:103 dilution was incubated for 30 min at room temperature with 1 × 107 125I-iodinated cells followed by two washes in phosphate-buffered saline. The antibodybound radioiodinated cells were lysed with 0.5 ml of 0.5% nonidet P-40 (NP-40) (Shell Chemical Co., New York) in 10 mM Tris-HCl buffer (pH 8.0) that contained 10 mM iodoacetamide and then spun at 3,000 rpm for 10 rain to remove the nuclear debris. F(ab')2 fragments of affinity column purified goat antimouse IgG reagent were coupled to cyanogen bromine-activated Sepharose 4B gel (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc.) at 3 mg/ml gel and used to bring down the antibody-bound, radiolabeled surface antigens. The immunoprecipitates were then washed twice with buffer that contained 10 mM Tris HC1 (pH 8.0), 0.5 M LiC1, and 0.1% NP-40 followed by a third wash with the same buffer that contained 0.1% sodium dodecyl sulfate (SDS). The bound 125I-labeled surface antigens were eluted by boiling the beads with 4M urea and 2% SDS in 0.1 M Tris HCI (pH 8.0) buffer and electrophoresed on SDSpolyacrylamide gels as described by Laemmli (8) with 1.5-ram-thick slab gels with a 5-20% gradient of acrylamide.
Results and Discussion
Mouse splenocyte-myeloma cell hybrids that produced antibodies that reacted with normal T but not B cells were screened by indirect immunofluorescent analysis on a cytofluorograph. One such hybrid, which produced an antibody that reacted with the majority of SRBC-rosetting cells, was cloned 8-10 times in vitro and implanted subcutaneously into a nude mouse. The resulting high-titered antiserum was shown to recognize a p69,71 by immunoprecipitation experiments. This was performed by harvesting T cells that were stimulating in culture for 5 d with concanavalin A (Con A) and surface labeling the cells with ~25I by the lactoperoxidase-catalyzed reaction. T h e cells were reacted with specific antibody, washed, a n d lysed with NP-40 detergent. T h e i m m u n e complexes in the lysate were absorbed onto Sepharose CL-4B beads that h a d been coupled with F(ab')z fragments of goat-antimouse IgG reagent, a n d analyzed by S D S -p o l y a c r y l a m i d e gel electrophoresis.
U n d e r nonreducing conditions, the total cell lysate of the Con A-activated blasts gave more than 40 discernible bands that ranged from 5,000 to 220,000 d a h o n s (Fig.  1 a) . T h e i m m u n o p r e c i p i t a t e performed with the monoclonal a n t i b o d y gave two distinct bands with molecular weights of 69,000 and 71,000 daltons (Fig. 1 b) . As a control, a normal n u d e mouse serum did not precipitate any discernible c o m p o n e n t (Fig. 1 c) . T o exclude the possibility that the defined antigen was a c o m p o n e n t of FCS that had been passively absorbed onto the cells, the a n t i b o d y was first incubated with an excess of FCS before reaction with the labeled cells as shown in Fig. 1 d. Similar results were obtained with other positive target cells.
T h e specificity of the a-Leu 1 nude mouse serum was studied by indirect immuno fluorescence on a cytofluorograph with techniques that have been previously described (5). Background reactivity was assessed by using a serum at the same dilution (1:104) from a tumor-free a n i m a l of the same strain. reacted with peripheral blood T cells, and with tonsillar B cells. As can be seen, the great majority of T cells exhibited binding to a-Leu 1 above background. In contrast, B cells did not fluoresce above a normal serum control.
As shown in Table I , 80-95% of SRBC-rosetting cells from the peripheral blood of 20 normal individuals and >95% of thymocytes from 5 children undergoing cardiac surgery were found to express the Leu 1 antigen. Ongoing studies in our laboratory (Memorial Sloan-Kettering Cancer Center, New York) indicate that the 5-20% Erosette-positive, Leu 1-negative cells do not express other thymus-dependent surface antigens. This finding suggests that t~-p69,71 defines the entire population of circulating thymus-derived lymphocytes, and that some cells of a non-thymic origin may carry the receptor for SRBC (9) .
Data presented in Table I also indicate that a-Leu 1 does not react with normal lymphoid or hematopoietic cells that do not carry thymus-dependent markers. Thus, bone marrow cells, monocytes, and B cells from the peripheral blood, tonsils, and spleen were found to be unreactive with c~-Leu 1. Splenocytes were obtained from patients with Hodgkin's disease that had been splenectomized for staging. Spleens that were pathologically positive for Hodgkin's disease were not included.
Because of the demonstration that a-Leu 1 was unreactive with normal B cells, it was surprising to find that this antibody reacted with Ig + cells from 11 of 14 patients examined who had the clinical diagnosis of chronic lymphatic leukemia (CLL) (Fig.  2 C; and Table I ). It should be mentioned that the great majority of cells from patients with CLL have several characteristics that indicate that the malignant cells are of B cell origin. These include surface markers characteristic of B cells and the capacity to differentiate into plasma cells under certain conditions (10) . Furthermore, none of the 14 cases examined in this report reacted with monoclonal antibodies to thymus-dependent antigens, includingTH2 (5) (data not shown). The possibility that the expression of Leu 1 by surface (s)Ig + CLL cells resulted from transformation events that can also be triggered in normal B cells seems unlikely in view of the demonstration that Epstein-Barr virus (EBV)-infected B cell lymphoblasts were Leu 1 negative (Table I ).
An alternative explanation of our results lies in the possibility that CLL represents a malignancy of a small subpopulation of Leu 1-positive B lymphocytes. However, this does not seem likely in light of the demonstration that this subset was not (12) , and receptors for IgM (13) . Our findings, therefore, raise questions regarding the classification of certain human lymphocyte surface antigens as markers of particular differentiation pathways, because induction of the determinant recognized by a-Leu 1 seems to take place under at least one set of pathological conditions outside the thymic environment. Finally, it is relevant to our studies that malignant transformation of murine lymphocytes may be associated with the induction of membrane alloantigens that have a normal tissue distribution that is restricted by either strain phenotype or by cell lineage (14) . The mouse Gtx system exemplifies such an antigen because its distribution on normal lymphoid cells is restricted to thymus-dependent lymphocytes of certain strains, but it is found on both thymic and nonthymic leukemias of Gix + and Gix-strains (2) . It is also notable that Gtx is associated with a membrane complex of 69,000 and 71,000 daltons and that this complex shares biochemical and antigenic properties with the major glycoprotein component for the murine leukemia virus envelope (15) (16) (17) . We are therefore investigating a possible relationship between the human p69,71 complex and the murine Gxx system.
Summary
In the course of generating monoclonal antibodies to human thymus-dependent differentiation antigens, we were able to define specificities shared by T cells and by cells from patients with chronic lymphatic leukemia that were not detectable on normal B cells. In particular, one of these antibodies was reactive by indirect immunofluorescence with >95% of the thymocytes and 80-95% of nonadherent sheep erythrocyte-rosetting peripheral blood lymphocytes (PBL), but was unreactive with normal B cells or cell lines derived from PBL by Epstein-Barr virus transformation. However, the leukemic cells from 11 of 14 patients with B-type chronic lymphatic leukemia were found to express detectable concentrations of this surface determinant.
The target antigen recognized by this monoclonal antibody was shown by immu-noprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis to be a p69,71 complex. Our findings suggest a possible relationship between this antigen and the previously described Gtx system in the mouse.
